Department of Biology, College of the Holy Cross, Worcester MA, USA.
Department of Chemistry, College of the Holy Cross, Worcester MA, USA.
J Complement Integr Med. 2023 Jun 7;20(3):662-664. doi: 10.1515/jcim-2023-0129. eCollection 2023 Sep 1.
As the COVID-19 pandemic continues, a prolonged post-infectious syndrome or "long COVID" has been reported. This is a multi-organ post viral syndrome that persists well after infection. Currently, there is no available treatment. Emerging evidence credits this "long COVID" syndrome to ongoing inflammatory response following resolution of symptoms during infection. An omega-three fatty acid derivative used in the treatment of hypertriglyceridemia, Icosapent Ethyl (IPE, VASCEPA/Epadel), was previously shown to reduce cardiovascular risk, likely via immunomodulatory effects. This study aims to evaluate the effectiveness of Icosapent Ethyl.
Following previous publications in treatment of severe acute COVID-19, we analyze two case studies of adults treated with Icosapent Ethyl.
After experiencing the symptoms of Long Covid, both individuals analyzed across two case studies experiences a resolution of symptoms after treatment with Icosapent Ethyl.
After review and analysis we conclude that Icosapent Ethyl may have been a determining factor in Long COVID symptom resolution and should be studied further.
随着 COVID-19 大流行的持续，有报道称出现了一种长期的感染后综合征或“长新冠”。这是一种多器官的病毒后综合征，在感染后持续存在。目前尚无可用的治疗方法。新出现的证据将这种“长新冠”综合征归因于感染症状缓解后持续存在的炎症反应。一种用于治疗高三酰甘油血症的ω-3 脂肪酸衍生物，依泽替米贝（IPE，VASCEPA/Epadel），先前被证明可以降低心血管风险，可能通过免疫调节作用。本研究旨在评估依泽替米贝的疗效。
在先前发表的治疗严重急性 COVID-19 的研究之后，我们分析了两例接受依泽替米贝治疗的成年人病例。
在经历了长新冠的症状后，这两个案例研究中的个体在接受依泽替米贝治疗后症状得到缓解。
经过审查和分析，我们得出结论，依泽替米贝可能是长新冠症状缓解的决定因素，应该进一步研究。
